USPTO serial 79208607
E
Reviewed by CopyMark Law Group
Reg. 5603613Status 709
- Filing date
- Status date
- Registration date
- Nov 13, 2018
- Examiner
- TURNER, LAUREN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with E?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Susan Piasick Christoff
Susan Piasick Christoff Cooley LLP1299 Pennsylvania Ave, NWSuite 700Washington, DC 20004Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for transport of therapeutic agents; pharmaceutical preparations, namely, engineered exosomes that deliver protein for genetic therapy; biological preparations comprising exosome for medical use; biological reagents comprising exosome for medical use; mixed biological preparations comprising exosome for pharmaceutical and medical use; diagnostic reagents comprising exosome for medicinal use in the fields of biology, genetic engineering and pharmaceuticals; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle-based nucleic acid therapeutics for the prevention and treatment of infectious diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, mitochondrial disease, neuromuscular disease, inflammatory diseases and autoimmune disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in the detection of infectious diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, mitochondrial disease, neuromuscular disease, inflammatory diseases and autoimmune disorders | SECTION 71 - CANCELLED | — |
| 042 | Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; biological research; clinical research in the field of transformational therapeutics; providing medical and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named E
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 5, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 5, 2026 | INPC | INVALIDATION PROCESSED | — |
| Jan 30, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 30, 2025 | C71T | CANCELLED SECTION 71 | — |
| Nov 13, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 4, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 30, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 8, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 20, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 20, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 13, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 13, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 28, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 28, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 24, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 8, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 8, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 27, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 27, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 27, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 15, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 31, 2018 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jan 30, 2018 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Jan 11, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 11, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 11, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 16, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 15, 2017 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Dec 13, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 13, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 8, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 17, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 17, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 10, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 9, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 6, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 2, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 2, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 1, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |